

Referensi

1. Abida, W., Beltran, H. and Raychaudhuri, R. (2025) "State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer," American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. doi:10.1200/edbk-25-473636.
2. Azimi, Y. et al. (2024) "Inhibitory effect of miR-377 on the proliferative and invasive behaviors of prostate cancer cells through the modulation of MYC mRNA via its interaction with BCL-2/Bax, PTEN, and CDK4," *Genes & Cancer*, 15, p. 28. doi:10.18632/genesandcancer.236.
3. Badiola, I. (2010) "MicroRNA Implication in Cancer," *Notulae Scientia Biologicae*, 2(1), p. 7. doi:10.15835/nsb214566.
4. Baumgart, S.J. and Haendler, B. (2017) "Exploiting Epigenetic Alterations in Prostate Cancer," *International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute*, p. 1017. doi:10.3390/ijms18051017.
5. Bazarbashi, S., Su, W.-P., Wong, S. W., Singarachari, R. A., Rawal, S., Волкова, М. И., & Bastos, D. A. (2021). A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries [Review of A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries]. *Oncology and Therapy*, 9(2), 311. Adis, Springer Healthcare. <https://doi.org/10.1007/s40487-021-00160-6>.

6. Dai, X. et al. (2017) “miR 21 is involved in transforming growth factor β 1 induced chemoresistance and invasion by targeting PTEN in breast cancer,” *Oncology Letters* [Preprint]. doi:10.3892/ol.2017.7007.
7. Davoudi, F., Moradi, A., Becker, T. M., Lock, J. G., Abbey, B., Fontanarosa, D., Haworth, A., Clements, J. A., Ecker, R., & Batra, J. (2023). Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer [Review of Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer]. *Current Treatment Options in Oncology*, 24(10), 1451. Springer Science+Business Media. <https://doi.org/10.1007/s11864-023-01121-z>
8. Farmer, A. (2016) The Roles of Nuclear Receptor NR4A1 in Cancer Cell Proliferation and Skeletal Muscle Differentiation. doi:10.21007/etd.cghs.2016.0411.
9. Fonseca, N.M., Roberts, M.E. and Wyatt, A.W. (2021) “A marrow-minded look at immune checkpoint blockade resistance in metastatic castration resistant prostate cancer,” *Translational Andrology and Urology*. AME Publishing Company. doi:10.21037/tau-20-1205.
10. Galvão-Lima, L.J. et al. (2021) “miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools,” *BioMedical Engineering OnLine*. BioMed Central. doi:10.1186/s12938-021-00857-9.

11. Ge, R. et al. (2020) “Epigenetic modulations and lineage plasticity in advanced prostate cancer,” *Annals of Oncology*. Elsevier BV, p. 470. doi:10.1016/j.annonc.2020.02.002.
12. Geretto, M. et al. (2017) “Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators,” *PubMed*, 7(6), p. 1350. Available at: <https://pubmed.ncbi.nlm.nih.gov/28670496> (Accessed: February 2025).
13. Giunchi, F., Fiorentino, M. and Loda, M. (2018) “The Metabolic Landscape of Prostate Cancer,” *European Urology Oncology*. Elsevier BV, p. 28. doi:10.1016/j.euo.2018.06.010.
14. Heidegger, I. et al. (2022) “Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review,” *Therapeutic Advances in Medical Oncology*. SAGE Publishing. doi:10.1177/17588359221081922.
15. Hötker, A. M., Mazaheri, Y., Aras, Ö., Zheng, J., Moskowitz, C. S., Gondo, T., Matsumoto, K., Hricak, H., & Akin, O. (2016). Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI. *American Journal of Roentgenology*, 206(4), 756. <https://doi.org/10.2214/ajr.15.14912>
16. Ibraheem, N., Abdelglil, M., Wanees, A., Aosmali, A., Shahid, M. H., & Mithany, R. H. (2024). Innovations and Emerging Trends in Prostate Cancer Management: A Literature Review [Review of Innovations and Emerging

- Trends in Prostate Cancer Management: A Literature Review]. *Cureus*. Cureus, Inc. <https://doi.org/10.7759/cureus.73128>
17. Jadvar, H., Calais, J., Fanti, S., Feng, F. Y., Greene, K. L., Gulley, J. L., Hofman, M. S., Koontz, B. F., Lin, D. W., Morris, M. J., Rowe, S. P., Royce, T. J., Salami, S. S., Savir-Baruch, B., Srinivas, S., & Hope, T. A. (2021). Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. *Journal of Nuclear Medicine*, 63(1), 59. <https://doi.org/10.2967/jnumed.121.263262>
 18. Khorasanchi, A., Hong, F., Yang, Y., Singer, E. A., Wang, P., Li, M., Zheng, L., Monk, P., Mortazavi, A., & Meng, L. (2025). Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches [Review of Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches]. *Cancer Drug Resistance*. <https://doi.org/10.20517/cdr.2024.173>
 19. Labbé, M. et al. (2020) “microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation,” *Molecular Cancer*. BioMed Central. doi:10.1186/s12943-020-01186-6.
 20. Li, J. et al. (2017) “Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration,” *The Prostate*, 77(9), p. 1000. doi:10.1002/pros.23356.
 21. Lin, Z. et al. (2019) “MiR-21-3p Plays a Crucial Role in Metabolism Alteration of Renal Tubular Epithelial Cells during Sepsis Associated Acute Kidney

- Injury via AKT/CDK2-FOXO1 Pathway,” *BioMed Research International*, 2019, p. 1. doi:10.1155/2019/2821731.
22. Liu, M. et al. (2019) “MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2,” *Cellular & Molecular Biology Letters*, 24(1). doi:10.1186/s11658-019-0168-7.
 23. Marshall, C. H., & Antonarakis, E. S. (2020). Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches. *Cancer Treatment and Research Communications*, 23, 100164. <https://doi.org/10.1016/j.ctarc.2020.100164>
 24. Mauro, G.D. et al. (2023) “Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos,” *Scientific Reports*, 13(1). doi:10.1038/s41598-023-33116-z.
 25. Mazumder, S. et al. (2018) “Liquid biopsy: miRNA as a potential biomarker in oral cancer,” *Cancer Epidemiology*. Elsevier BV, p. 137. doi:10.1016/j.canep.2018.12.008.
 26. Miyoshi, J. et al. (2017) “MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer,” *Scientific Reports*, 7(1). doi:10.1038/srep43393.
 27. Mortazavi, D. et al. (2022) “Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer,” *Journal of Oncology*. Hindawi Publishing Corporation, p. 1. doi:10.1155/2022/4889807.

28. Moreira□Silva, F., Henrique, R., & Jerónimo, C. (2022). From Therapy Resistance to Targeted Therapies in Prostate Cancer [Review of From Therapy Resistance to Targeted Therapies in Prostate Cancer]. *Frontiers in Oncology*, 12. Frontiers Media. <https://doi.org/10.3389/fonc.2022.877379>
29. Morozov, V., Li, Y., Clowers, M. M., & Ishov, A. M. (2017). Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer. *Oncotarget*, 8(37), 62131. <https://doi.org/10.18632/oncotarget.19100>
30. Nickols, N. G., Nazarian, R., Zhao, S. G., Tan, V. M., Uzunangelov, V., Xia, Z., Baertsch, R., Neeman, E., Gao, A. C., Thomas, G., Howard, L. E., Hoedt, A. M. D., Stuart, J. M., Goldstein, T. C., Chi, K., Gleave, M., Graff, J. N., Beer, T. M., Drake, J. M., ... Rettig, M. B. (2019). MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. *Prostate Cancer and Prostatic Diseases*, 22(4), 531. <https://doi.org/10.1038/s41391-019-0134-5>
31. Niscola, P. et al. (2024) "Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies," *Current Oncology*. Multidisciplinary Digital Publishing Institute, p. 6632. doi:10.3390/currenol31110490.
32. Nunzio, C.D. et al. (2018) "Castration-resistance prostate cancer: what is in the pipeline?," *Minerva Urology and Nephrology*. doi:10.23736/s0393-2249.17.02976-9.

33. Oakley, C. K., & Teply, B. A. (2025). Optimal use, combinations, and sequencing of therapies in advanced prostate cancer. *Expert Review of Clinical Pharmacology*. <https://doi.org/10.1080/17512433.2025.2451643>
34. Patel, L.R. and Pritchard, C.C. (2023) “Molecular testing of DNA damage response pathways in prostate cancer patients,” *Current Opinion in Oncology*. Lippincott Williams & Wilkins, p. 224. doi:10.1097/cco.0000000000000934.
35. Santos, J. et al. (2020) “The Emerging Role of MicroRNAs and Other Non-Coding RNAs in Cancer Cachexia,” *Cancers*. Multidisciplinary Digital Publishing Institute, p. 1004. doi:10.3390/cancers12041004.
36. Schrecengost, R. S., & Knudsen, K. E. (2013). Molecular Pathogenesis and Progression of Prostate Cancer [Review of Molecular Pathogenesis and Progression of Prostate Cancer]. *Seminars in Oncology*, 40(3), 244. Elsevier BV. <https://doi.org/10.1053/j.seminoncol.2013.04.001>.
37. Sedelaar, J. P. M., & Schalken, J. A. (2015, May 8). The need for a personalized approach for prostate cancer management. In *BMC Medicine* (Vol. 13, Issue 1). BioMed Central. <https://doi.org/10.1186/s12916-015-0344-1>
38. Shore, N. D., Moul, J. W., Pienta, K. J., Czernin, J., King, M. T., & Freedland, S. J. (2023). Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification [Review of Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification]. *Prostate Cancer and Prostatic Diseases*, 27(2), 192. Springer Nature. <https://doi.org/10.1038/s41391-023-00712-z>

39. Smith, J.L. et al. (2017) “A MicroRNA Screen Identifies the Wnt Signaling Pathway as a Regulator of the Interferon Response during Flavivirus Infection,” *Journal of Virology*, 91(8). doi:10.1128/jvi.02388-16.
40. Soares, S. et al. (2021) “The Influence of miRNAs on Radiotherapy Treatment in Prostate Cancer – A Systematic Review,” *Frontiers in Oncology*. *Frontiers Media*. doi:10.3389/fonc.2021.704664.
41. Syeda, Z.A. et al. (2020) “Regulatory Mechanism of MicroRNA Expression in Cancer,” *International Journal of Molecular Sciences*. Multidisciplinary Digital Publishing Institute, p. 1723. doi:10.3390/ijms21051723.
42. Teo, M. Y., Rathkopf, D. E., & Kantoff, P. W. (2019). Treatment of Advanced Prostate Cancer [Review of Treatment of Advanced Prostate Cancer]. *Annual Review of Medicine*, 70(1), 479. *Annual Reviews*. <https://doi.org/10.1146/annurev-med-051517-011947>
43. Toraih, E.A. et al. (2017) “MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma,” *Oxidative Medicine and Cellular Longevity*, 2017(1). doi:10.1155/2017/3269379.
44. Vlachostergios, P.J., Puca, L. and Beltran, H. (2017) “Emerging Variants of Castration-Resistant Prostate Cancer,” *Current Oncology Reports*. Springer Science+Business Media. doi:10.1007/s11912-017-0593-6.
45. Wei, B., Huang, B. and Zhao, X. (2023) “An overview of biochemical technologies for the cancer biomarker miR-21 detection,” *Analytical Sciences*. Springer Nature, p. 815. doi:10.1007/s44211-023-00304-w.

46. Xiang, Z. et al. (2025) "MiRNA expression profiling and clinical implications in prostate cancer across various stages," *Scientific Reports*, 15(1). doi:10.1038/s41598-025-92091-9.
47. Yamazaki, H., Suzuki, G., Masui, K., Aibe, N., Kimoto, T., Yamada, K., Okihara, K., Hongo, F., Okumi, M., Shiraishi, T., Fujihara, A., Yoshida, K., Nakamura, S., Kato, T., Hashimoto, Y., & Okabe, H. (2024). The influence of Gleason score ≤ 6 histology on the outcome of high-risk localized prostate cancer after modern radiotherapy. *Scientific Reports*, 14(1). <https://doi.org/10.1038/s41598-024-55457-z>
48. Yehya, A., Ghamlouche, F., Zahwe, A., Zeid, Y., Wakimian, K., Mukherji, D., & Abou Kheir, W. (2022). Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo [Review of Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo]. *Cancer Drug Resistance*, 5(3), 667. <https://doi.org/10.20517/cdr.2022.15>.
49. Zadra, G. and Loda, M. (2017) "Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities," *Cold Spring Harbor Perspectives in Medicine*. Cold Spring Harbor Laboratory Press. doi:10.1101/cshperspect.a030569.
50. Zheng, D. et al. (2013) "Role of WNT7B-induced Noncanonical Pathway in Advanced Prostate Cancer," *Molecular Cancer Research*, 11(5), p. 482. doi:10.1158/1541-7786.mcr-12-0520.